BMS-103
BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM). BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1675202-86-4
- Formule: C25H29NO4
- Masse moléculaire:407.50
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
5.7 μM
Compound: A1
|
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37226718] |
Chemical Information
-
CAS No. 1675202-86-4
-
Masse moléculaire 407.50
-
Formule C25H29NO4
-
SMILES
CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)